Novartis Ag Share Price (NYSE: NVS)

$126.6

▲

0.05

(0.04%)

Last updated on September 3, 2025 at 1:29 am IST

$₹

Check the interactive Novartis Ag Stock chart to analyse performance

Novartis Ag stock performance

as on September 3, 2025 at 1:29 am IST

Today's Low:$125.77
Today's High:$126.60
$126.60
0.66%
Downside
Day's Volatility :0.66%
Upside
0.0%
52 Weeks Low:$96.06
52 Weeks High:$128.03
$126.60
24.12%
Downside
52 Weeks Volatility :24.97%
Upside
1.12%

Novartis Ag Stock Returns

Period	Novartis Ag	Sector (Health Care)	Index (Russel 2000)
3 Months	8.22%	3.5%	0.0%
6 Months	13.11%	-7.7%	0.0%
1 Year	6.79%	-12.6%	0.0%
3 Years	58.64%	10.0%	-2.3%

Novartis Ag Key Stats

Check Novartis Ag key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$126.55
Open	$126.34
Today's High	$126.6
Today's Low	$125.77
Market Capitalization	$245.0B
Today's Volume	$761.2K
52 Week High	$128.03
52 Week Low	$96.062
Revenue TTM	$55.2B
EBITDA	$23.6B
Earnings Per Share (EPS)	$6.86
PE Ratio	18.45
Dividend Yield	3.16%
Profit Margin	24.74%
Quarterly Earnings Growth YOY	0.3%
Return On Equity TTM	32.49%

Stock Returns calculator for Novartis Ag Stock including INR - Dollar returns

The Novartis Ag stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Novartis Ag investment value today

Current value as on today

₹1,11,875

Returns

₹11,875

(+11.88%)

Returns from Novartis Ag Stock

₹6,835 (+6.84%)

Dollar Returns*

₹5,040 (+5.04%)

Indian investors sentiment towards Novartis Ag Stock

-28.14%

Period: Aug 3, 2025 to Sep 2, 2025. Change in 30 Days versus previous period

Investment in Novartis Ag Shares from India has dropped by -28.14% over the past 30 days, indicating reduced transactional activity.

-12%

Period: Aug 3, 2025 to Sep 2, 2025. Change in 30 Days versus previous period

Search interest for Novartis Ag Stock from India on INDmoney has decreased by -12% in the last 30 days, reflecting a downward trend in search activity.

Indian Mutual Funds that invest in Novartis Ag Stock

Name	Shares Held	Change in Shares	% of Assets
Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Direct Growth	2998	0.00	1.80%

Global Institutional Holdings in Novartis Ag

Name
Holdings %
Name
Holdings %
Dodge & Cox
0.55%
PRIMECAP Management Company
0.54%
Dimensional Fund Advisors, Inc.
0.47%
Fisher Asset Management, LLC
0.37%
Morgan Stanley - Brokerage Accounts
0.36%
Loomis, Sayles & Company LP
0.29%

Analyst Recommendation on Novartis Ag Stock

Rating

Trend

Buy

50%Buy

43%Hold

6%Sell

Based on 32 Wall street analysts offering stock ratings for Novartis Ag(by analysts ranked 0 to 5 stars)

Novartis Ag Share Price Target

What analysts predicted

Downside of 6.36%

Target:

$118.55

Current:

$126.60

Novartis Ag share price target is $118.55, a slight Downside of 6.36% compared to current price of $126.60 as per analysts' prediction.

Novartis Ag Stock Insights

Price Movement
In the last 6 months, NVS stock has moved up by 16.0%
Increasing Revenue
Novartis AG has shown consistent revenue growth over the last 7 quarters, increasing from $11.77 billion to $14.27 billion. This represents an average quarterly growth rate of 3.1%.
Decreasing Net Profit
Novartis AG has experienced a significant decline in net profit over the last two quarters. The profit fell from $3.60 billion to $4.02 million, showing an average decrease of 99.9% each quarter.
NVS vs ABBV (1 yr)
In the last 1 year, Abbvie Inc has given 7.2% return, outperforming this stock by 2.5%
Price to Sales
Novartis AG has a Price-to-Sales (P/S) ratio of 4.5, meaning that investors are willing to pay $4.5 for every $1 of sales the company generates. In comparison, Abbvie Inc has a higher P/S ratio of 6.4, indicating that investors pay more for each dollar of sales from Abbvie than they do for Novartis.

Novartis Ag Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$48.7B	↓ 8.44%
Net Income	$7.1B	↓ 43.33%
Net Profit Margin	14.68%	↓ 9.04%

	FY20	Y/Y Change
Revenue	$49.9B	↑ 2.51%
Net Income	$8.1B	↑ 12.94%
Net Profit Margin	16.18%	↑ 1.5%

	FY21	Y/Y Change
Revenue	$52.9B	↑ 5.97%
Net Income	$24.0B	↑ 197.58%
Net Profit Margin	45.43%	↑ 29.25%

	FY22	Y/Y Change
Revenue	$51.8B	↓ 1.98%
Net Income	$7.0B	↓ 71.05%
Net Profit Margin	13.42%	↓ 32.01%

	FY23	Y/Y Change
Revenue	$46.7B	↓ 9.97%
Net Income	$14.9B	↑ 113.52%
Net Profit Margin	31.83%	↑ 18.41%

	FY24	Y/Y Change
Revenue	$51.7B	↑ 10.85%
Net Income	$11.9B	↓ 19.59%
Net Profit Margin	23.09%	↓ 8.74%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$11.8B	↑ 0.45%
Net Income	$2.7B	↓ 68.3%
Net Profit Margin	22.72%	↓ 49.29%

	Q2 FY24	Q/Q Change
Revenue	$12.5B	↑ 5.77%
Net Income	$3.2B	↑ 20.76%
Net Profit Margin	25.94%	↑ 3.22%

	Q3 FY24	Q/Q Change
Revenue	$13.2B	↑ 5.27%
Net Income	$3.2B	↓ 1.76%
Net Profit Margin	24.21%	↓ 1.73%

	Q4 FY24	Q/Q Change
Revenue	$13.6B	↑ 2.93%
Net Income	$2.8B	↓ 11.63%
Net Profit Margin	20.78%	↓ 3.43%

	Q1 FY25	Q/Q Change
Revenue	$13.6B	↑ 0.46%
Net Income	$3.6B	↑ 27.96%
Net Profit Margin	26.48%	↑ 5.7%

	Q2 FY25	Q/Q Change
Revenue	$14.3B	↑ 4.84%
Net Income	$4.0M	↓ 99.89%
Net Profit Margin	0.03%	↓ 26.45%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$34.3B	↓ 1.46%

	FY20	Y/Y Change
Profit	$34.8B	↑ 1.53%

	FY21	Y/Y Change
Profit	$37.0B	↑ 6.42%

	FY22	Y/Y Change
Profit	$36.3B	↓ 1.8%

	FY23	Y/Y Change
Profit	$34.2B	↓ 5.93%

	FY24	Y/Y Change
Profit	$38.9B	↑ 13.77%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$8.7B	↓ 0.63%

	Q2 FY24	Q/Q Change
Profit	$9.3B	↑ 6.85%

	Q3 FY24	Q/Q Change
Profit	$9.9B	↑ 6.92%

	Q4 FY24	Q/Q Change
Profit	$10.2B	↑ 2.98%

	Q1 FY25	Q/Q Change
Profit	$10.4B	↑ 1.55%

	Q2 FY25	Q/Q Change
Profit	$11.5M	↓ 99.89%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$13.6B	↓ 4.53%
Investing Cash Flow	$-2.2B	↓ 60.19%
Financing Cash Flow	$-13.6B	↑ 221.09%

	FY20	Y/Y Change
Operating Cash Flow	$13.7B	↑ 0.18%
Investing Cash Flow	$-13.2B	↑ 492.18%
Financing Cash Flow	$-2.2B	↓ 83.8%

	FY21	Y/Y Change
Operating Cash Flow	$15.1B	↑ 10.41%
Investing Cash Flow	$4.2B	↓ 131.92%
Financing Cash Flow	$-16.3B	↑ 636.59%

	FY22	Y/Y Change
Operating Cash Flow	$14.2B	↓ 5.54%
Investing Cash Flow	$1.5B	↓ 65.11%
Financing Cash Flow	$-20.6B	↑ 26.43%

	FY23	Y/Y Change
Operating Cash Flow	$14.5B	↑ 1.56%
Investing Cash Flow	$5.6B	↑ 281.2%
Financing Cash Flow	$-14.3B	↓ 30.56%

	FY24	Y/Y Change
Operating Cash Flow	$17.6B	↑ 21.86%
Investing Cash Flow	$-7.5B	↓ 234.26%
Financing Cash Flow	$-11.7B	↓ 17.76%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$2.3B	↓ 11.07%
Investing Cash Flow	$-899.0M	↓ 48.92%
Financing Cash Flow	$-5.2B	↑ 750.74%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$4.9B	↑ 115.23%
Investing Cash Flow	$-3.2B	↑ 256.73%
Financing Cash Flow	$-3.2B	↓ 38.03%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$6.3B	↑ 28.94%
Investing Cash Flow	$-374.0M	↓ 88.34%
Financing Cash Flow	$-382.0M	↓ 88.06%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$4.2B	↓ 33.3%
Investing Cash Flow	$-3.0B	↑ 710.96%
Financing Cash Flow	$-3.0B	↑ 684.29%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$3.6B	↓ 13.07%
Investing Cash Flow	$330.0M	↓ 110.88%
Financing Cash Flow	$-8.5B	↑ 185.31%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$6.7B	↑ 82.83%
Investing Cash Flow	$-2.2B	↓ 779.7%
Financing Cash Flow	$-5.2B	↓ 39.01%

Novartis Ag Technicals Summary

Sell

Neutral

Buy

Novartis Ag is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Novartis Ag Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Novartis Ag	7.4%	13.11%	6.79%	58.64%	46.0%
Eli Lilly And Company	-4.74%	-21.2%	-23.41%	138.77%	385.44%
Johnson & Johnson	3.58%	7.3%	5.99%	8.57%	19.23%
Merck & Co. Inc.	5.33%	-9.73%	-27.84%	-2.66%	-1.31%
Novo Nordisk A/s	15.67%	-37.86%	-58.56%	9.01%	73.43%
Abbvie Inc	6.7%	-0.54%	6.43%	52.92%	129.02%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Novartis Ag	18.45	18.45	1.38	9.02	0.32	0.12	0.03	21.69
Eli Lilly And Company	47.85	47.85	1.06	22.83	0.86	0.17	0.01	20.38
Johnson & Johnson	18.97	18.97	1.08	10.85	0.3	0.08	0.03	32.6
Merck & Co. Inc.	12.96	12.96	0.83	8.93	0.35	0.13	0.04	19.57
Novo Nordisk A/s	14.51	14.51	1.67	24.83	0.79	0.22	0.03	37.82
Abbvie Inc	100.19	100.19	0.44	11.97	1.13	0.09	0.03	-0.1

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Novartis Ag	Buy	$245.0B	46.0%	18.45	24.74%
Eli Lilly And Company	Buy	$656.7B	385.44%	47.85	25.91%
Johnson & Johnson	Buy	$426.7B	19.23%	18.97	25.0%
Merck & Co. Inc.	Buy	$210.1B	-1.31%	12.96	25.79%
Novo Nordisk A/s	Buy	$248.7B	73.43%	14.51	35.61%
Abbvie Inc	Buy	$371.7B	129.02%	100.19	6.45%

Novartis Ag Dividend announcements

Novartis Ag Dividends March, 2025
In the quarter ending March,2025. Novartis Ag has declared dividend of $3.87

About Novartis Ag

Novartis AG engages in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

Organization	Novartis Ag
Employees	75883
CEO	Dr. Vasant Narasimhan M.D.
Industry	Health Technology

Key Management of Novartis Ag

Name	Title
Dr. Vasant Narasimhan M.D.	Chief Executive Officer
Mr. Harry Kirsch	Chief Financial Officer
Mr. Victor Bulto	President of US
Dr. Patrick Horber M.D.	President of International
Dr. Steffen Lang Ph.D.	President of Operations
Paul Penepent	Head of Group Financial Reporting and Accounting
Ms. Sloan Simpson	Global Head of Investor Relations
Ms. Karen L. Hale	Chief Legal & Compliance Officer
Dr. Robert Kowalski Pharm.D.	Chief People & Organization Officer
Dr. Linda W. Armstrong M.D.	Global Head of Respiratory Development

Important FAQs about investing in NVS Stock from India :

What is Novartis Ag share price today?

Novartis Ag share price today is $126.60 as on September 3, 2025 at 1:29 am IST at the close of the market. Novartis Ag share today touched a day high of $126.60 and a low of $125.77.

What is the 52 week high and 52 week low for Novartis Ag share?

Novartis Ag share touched a 52 week high of $128.03 and a 52 week low of $96.06. Novartis Ag stock price today i.e. September 3, 2025 at 1:29 am IST is closed at $126.60, lower by 1.12% versus the 52 week high.

How to invest in Novartis Ag Stock (NVS) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Novartis Ag on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Novartis Ag Shares that will get you 0.0118 shares as per Novartis Ag share price of $126.60 per share as on September 3, 2025 at 1:29 am IST.

What is the minimum amount required to buy Novartis Ag Stock (NVS) from India?

Indian investors can start investing in Novartis Ag (NVS) shares with as little as ₹88.16 or $1 (as of September 03, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹881.60 in Novartis Ag stock (as per the Rupee-Dollar exchange rate as on September 03, 2025). Based on Novartis Ag share’s latest price of $126.60 as on September 3, 2025 at 1:29 am IST, you will get 0.0790 shares of Novartis Ag. Learn more about fractional shares .

What are the returns that Novartis Ag has given to Indian investors in the last 5 years?

Novartis Ag stock has given 46.0% share price returns and 20.77% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?